PortfoliosLab logoPortfoliosLab logo
SGMO vs. MRSN
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

SGMO vs. MRSN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Sangamo Therapeutics, Inc. (SGMO) and Mersana Therapeutics, Inc. (MRSN). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

SGMO vs. MRSN - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
SGMO
Sangamo Therapeutics, Inc.
-38.07%-58.82%87.74%-82.70%-58.13%-51.94%86.44%-27.09%-30.00%81.22%
MRSN
Mersana Therapeutics, Inc.
0.52%-19.08%-38.36%-60.41%-5.79%-76.63%364.40%40.44%-75.17%17.36%

Fundamentals

Market Cap

SGMO:

$87.84M

MRSN:

$145.02M

EPS

SGMO:

-$0.41

MRSN:

-$14.05

PS Ratio

SGMO:

1.97

MRSN:

4.37

Total Revenue (TTM)

SGMO:

$39.55M

MRSN:

$33.18M

Gross Profit (TTM)

SGMO:

$25.32M

MRSN:

$32.89M

EBITDA (TTM)

SGMO:

-$117.16M

MRSN:

-$66.25M

Returns By Period


SGMO

1D
5.35%
1M
-39.50%
YTD
-38.07%
6M
-61.44%
1Y
-54.38%
3Y*
-47.13%
5Y*
-53.74%
10Y*
-27.19%

MRSN

1D
1M
YTD
6M
1Y
3Y*
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

SGMO vs. MRSN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SGMO
SGMO Risk / Return Rank: 1616
Overall Rank
SGMO Sharpe Ratio Rank: 1818
Sharpe Ratio Rank
SGMO Sortino Ratio Rank: 2323
Sortino Ratio Rank
SGMO Omega Ratio Rank: 2323
Omega Ratio Rank
SGMO Calmar Ratio Rank: 99
Calmar Ratio Rank
SGMO Martin Ratio Rank: 88
Martin Ratio Rank

MRSN
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SGMO vs. MRSN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Sangamo Therapeutics, Inc. (SGMO) and Mersana Therapeutics, Inc. (MRSN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


SGMOMRSNDifference

Sharpe ratio

Return per unit of total volatility

-0.51

Sortino ratio

Return per unit of downside risk

-0.26

Omega ratio

Gain probability vs. loss probability

0.97

Calmar ratio

Return relative to maximum drawdown

-0.87

Martin ratio

Return relative to average drawdown

-1.54

SGMO vs. MRSN - Sharpe Ratio Comparison


Loading graphics...

Sharpe Ratios by Period


SGMOMRSNDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.51

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.51

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.29

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.16

Correlation

The correlation between SGMO and MRSN is 0.36, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

SGMO vs. MRSN - Dividend Comparison

Neither SGMO nor MRSN has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

SGMO vs. MRSN - Drawdown Comparison


Loading graphics...

Drawdown Indicators


SGMOMRSNDifference

Max Drawdown

Largest peak-to-trough decline

-99.50%

Max Drawdown (1Y)

Largest decline over 1 year

-69.70%

Max Drawdown (5Y)

Largest decline over 5 years

-98.05%

Max Drawdown (10Y)

Largest decline over 10 years

-99.06%

Current Drawdown

Current decline from peak

-99.48%

Average Drawdown

Average peak-to-trough decline

-83.93%

Ulcer Index

Depth and duration of drawdowns from previous peaks

39.13%

Volatility

SGMO vs. MRSN - Volatility Comparison


Loading graphics...

Volatility by Period


SGMOMRSNDifference

Volatility (1M)

Calculated over the trailing 1-month period

28.34%

Volatility (6M)

Calculated over the trailing 6-month period

78.81%

Volatility (1Y)

Calculated over the trailing 1-year period

108.44%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

106.51%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

95.01%

Financials

SGMO vs. MRSN - Financials Comparison

This section allows you to compare key financial metrics between Sangamo Therapeutics, Inc. and Mersana Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
14.23M
11.01M
(SGMO) Total Revenue
(MRSN) Total Revenue
Values in USD except per share items